Cytoplasmic localization of Jab1 and p27 Kip1 might be associated with invasiveness of papillary thyroid carcinoma.
p27(kip1) is a well known negative regulator of cell cycle progression. Jab1 directly binds to p27(kip1) and induces nuclear export and subsequent degradation. Recent studies have shown that overexpression of Jab1 and reduced expression of p27(kip1) are associated with advanced tumor stage and poor prognosis in several human cancers. Here, we evaluated 50 papillary thyroid carcinomas (PTC) and adjacent normal thyroid tissue samples by immunohistochemistry for Jab1 and p27(kip1) to elucidate expression levels and subcellular localization. Expression of Jab1 was markedly increased and that of p27(kip1) was reduced in the tumors compared with paired normal samples. Jab1 expression was inversely related to p27(kip1) expression. Jab1 was especially overexpressed within the invasive region compared to center of the tumors. Among clinicopathologic parameters, only tumor size was related with Jab1 (positively) and p27(kip1) expression (negatively) in the invasive region of the tumors. Both Jab1 and p27(kip1) were found predominantly in the cytoplasm of the tumor cells from the invasive regions compared to center of the tumors. The Ki-67 proliferative index was higher in the invasive region than in center of the tumors. A much stronger correlation with the Ki-67 index was noted when both Jab1 and p27(kip1) were simultaneously localized in the cytoplasm than when either Jab1 or p27(kip1) was localized in the cytoplasm alone. These data suggest that in addition to overexpression of Jab1 and reduced expression of p27(kip1), cytoplasmic localization of Jab1 and p27(kip1) are associated with increased cancer cell proliferation and might be related to the invasiveness of PTC.
Ahn
Jihyun
J
Division of Endocrinology and Metabolism, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
Hong
Soon Auck
SA
Lee
Seung-Eun
SE
Kim
Jaetaek
J
Oh
Yeon Sahng
YS
Park
Sung Jun
SJ
Chung
Yun Jae
YJ
D000328:Adult; D000075686:COP9 Signalosome Complex; D002291:Carcinoma, Papillary / Q000378:metabolism / Q000473:pathology*; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000378:metabolism*; D003593:Cytoplasm / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism*; D019394:Ki-67 Antigen / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000503:physiopathology*; D010447:Peptide Hydrolases / Q000378:metabolism*; D013961:Thyroid Gland / Q000378:metabolism; D013964:Thyroid Neoplasms / Q000378:metabolism / Q000473:pathology*
D047908:Intracellular Signaling Peptides and Proteins; D019394:Ki-67 Antigen; D050760:Cyclin-Dependent Kinase Inhibitor p27; D010447:Peptide Hydrolases; C501488:COPS5 protein, human; D000075686:COP9 Signalosome Complex